Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone650-266-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$112.96 million
Profitability
Miscellaneous
Employees505
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Fluidigm (NASDAQ:FLDM) Frequently Asked Questions
What is Fluidigm's stock symbol?
Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."
How were Fluidigm's earnings last quarter?
Fluidigm Co. (NASDAQ:FLDM) posted its quarterly earnings data on Thursday, February, 7th. The medical research company reported ($0.18) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.07. The medical research company earned $32.33 million during the quarter, compared to analyst estimates of $30.55 million. Fluidigm had a negative return on equity of 90.07% and a negative net margin of 52.24%. View Fluidigm's Earnings History.
When is Fluidigm's next earnings date?
What is the consensus analysts' recommendation for Fluidigm?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.
Has Fluidigm been receiving favorable news coverage?
Media stories about FLDM stock have trended somewhat negative on Saturday, InfoTrie reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fluidigm earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Fluidigm?
Fluidigm saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,553,536 shares, an increase of 59.3% from the December 31st total of 4,114,687 shares. Based on an average trading volume of 1,122,272 shares, the short-interest ratio is presently 5.8 days. Approximately 13.6% of the shares of the stock are short sold. View Fluidigm's Current Options Chain.
Who are some of Fluidigm's key competitors?
Some companies that are related to Fluidigm include Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Precipio (PRPO) and PositiveID (PSID).
What other stocks do shareholders of Fluidigm own?
Who are Fluidigm's key executives?
Fluidigm's management team includes the folowing people:
- Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
- Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
- Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Steven C. McPhail, Chief Commercial Officer (Age 65)
- Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
Who are Fluidigm's major shareholders?
Fluidigm's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Levin Capital Strategies L.P. (24.33%), BlackRock Inc. (5.44%), Millennium Management LLC (2.37%), RTW Investments LP (2.25%), Pura Vida Investments LLC (1.73%) and Acadian Asset Management LLC (1.37%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.
Which institutional investors are selling Fluidigm stock?
FLDM stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Connor Clark & Lunn Investment Management Ltd., D. E. Shaw & Co. Inc. and Northern Trust Corp. View Insider Buying and Selling for Fluidigm.
Which institutional investors are buying Fluidigm stock?
FLDM stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Millennium Management LLC, Pura Vida Investments LLC, Two Sigma Investments LP, Two Sigma Advisers LP, BlackRock Inc., Royce & Associates LP and Squarepoint Ops LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm.
How do I buy shares of Fluidigm?
Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fluidigm's stock price today?
One share of FLDM stock can currently be purchased for approximately $10.80.
How big of a company is Fluidigm?
Fluidigm has a market capitalization of $424.66 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Fluidigm employs 505 workers across the globe.
What is Fluidigm's official website?
How can I contact Fluidigm?
Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.
MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
